Efficacy, Tolerability and Safety of LAS41004 Formulations in a Psoriasis Plaque Test

NCT02111499 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: LAS41004-IMP1
DRUG: LAS41004 IMP2
DRUG: LAS41004 IMP3
DRUG: LAS41004 IMP4
DRUG: LAS41004 IMP6
DRUG: LAS41004 IMP5

Sponsor

Almirall, S.A.

Collaborators

[object Object]